New antibody studies boost hope for HIV cure:  Pioneering trials discover potential strategy to keep virus in check after stopping treatment

Antibody studies offer new hope for HIV prevention, cure: The Conference on Retroviruses and Opportunistic Infections highlighted promising advancements in HIV research amid funding cuts. Gilead Sciences presented data showing a single injection of lenacapavir could prevent HIV for a year, surpassing previous pre-exposure prophylaxis methods. Additionally, studies on broadly neutralizing antibodies demonstrated potential in controlling HIV without antiretroviral drugs, with some participants maintaining viral suppression for extended periods.

Paralyzed man stands again after receiving ‘reprogrammed’ stem cells:  Another man also regained some movement, but two others experienced minimal improvement

Stem cell therapy enables paralyzed man to stand again: In a small clinical trial involving people with paralysis, one (1) person was able to stand on his own after receiving injections of neural stem cells derived from induced pluripotent stem cells, demonstrating the potential of reprogrammed cells in facilitating nerve regeneration. Another participant regained some movement; however, two (2) others showed no significant improvement.

New advisory body needed to guide U.S. biomedical research policy, panel says:  National Academy of Medicine report cites failure to address health inequities, life expectancy

Panel: New body needed to guide US biomedical research: A panel convened by the National Academy of Medicine (NAM) recommends creating a new advisory body to guide United States biomedical research policy, aiming to better coordinate public and private funding to address health challenges like obesity and health inequities. The report highlights the need for a national strategic vision and improved funding collaboration across sectors, without necessarily increasing the NIH budget. It also emphasizes the importance of convergence science and diversifying the research workforce.

Dozens of new obesity drugs are coming: these are the ones to watch…Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with fewer side effects.

Next-generation obesity drugs are on the horizon: The success of semaglutide and tirzepatide have fueled the development of over 100 anti-obesity drug candidates, with an anticipated market value exceeding $100 billion by 2030. These emerging drugs, including bimagrumab to prevent muscle loss and retatrutide targeting multiple hormone receptors for enhanced weight loss, aim to improve efficacy and tolerability and address current treatment limitations.

Monkey study reveals science behind “choking under pressure”:  When a person (or monkey) is facing stakes that are too high, the stress can interfere with neurons, affecting how they direct the body to execute movements, a study suggests

Study with monkeys uncovers why people choke under pressure: A recent study with monkeys explores the phenomenon of “choking” under pressure, finding that heightened anxiety can interfere with brain function. The findings suggest that recreating “optimal” neural signatures could help humans enhance performance in high-pressure situations.

Male mosquitoes to be genetically engineered to poison females with semen in Australian research:  Approach could be used to limit outbreaks of mosquito-borne diseases, such as dengue fever, which results in 390m cases annually worldwide

Researchers engineer toxic male mosquitoes: Researchers have developed a method to control mosquito populations by genetically engineering male mosquitoes to produce venom proteins from spiders and sea anemones, which are injected into females during mating to reduce their lifespan. The “toxic male technique” could quickly suppress outbreaks of diseases such as dengue fever and Zika without extensive insecticide use, according to a study in Nature Communications.